Observational studyMedicine2025
Association between the oxidative balance score and gynecologic cancers from the National Health and Nutrition Examination Survey: An observational study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between Oxidative Balance Score and Colorectal Cancer: Insights from NHANES 1999-2018.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to examine the potential correlations between the oxidative balance score (OBS) and gynecological cancers susceptibility. A cross-sectional design was employed, utilizing datasets from the National Health and Nutrition Examination Survey spanning 2 decades from 1999 through 2018. Our investigation demonstrated that OBS exhibited significant protective correlations with gynecologic cancers (odds ratio [OR]=0.985, 95% confidence interval [CI]: 0.974-0.997, P=.011), specifically cervical cancer (OR=0.974, 95% CI: 0.952-0.996, P=.019) and ovarian cancer (OR=0.950, 95% CI: 0.912-0.990, P=.015). The protective correlations of OBS with gynecologic, cervical, and ovarian cancers displayed a dose-response relationship with elevated OBS levels, yielding ORs of 0.765 (95% CI: 0.614-0.952, P=.017), 0.474 (95% CI: 0.289-0.777, P=.003), and 0.397 (95% CI: 0.167-0.942, P=.036), respectively, in the uppermost quartile. The OBS demonstrates significant protective correlations with gynecological cancers, with notably marked effects identified in cervical and ovarian cancers. These observations provide innovative perspectives regarding the pathogenesis of gynecological neoplasms and carry important ramifications for clinical prevention and public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.